Triple Negative Breast Cancer
Conditions
Brief summary
The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).
Interventions
DRUGCamrelizumab
Intravenous (IV) infusion
DRUGApatinib
po.
DRUGNab-paclitaxel
IV infusion.
DRUGEpirubicin
IV infusion.
DRUGCyclophosphamide
IV infusion.
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
West China Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed breast cancer. * 18-75 Years, female. * Early or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression). * Tumor stage: II-III. * ECOG Performance Status of 0-1. * life expectancy is not less than 3 months. * at least one measurable lesion according to RECIST 1.1. * Adequate hematologic and organ function. * Must be willing to use an adequate method of contraception for the course of the study.
Exclusion criteria
* Stage Ⅳ (metastatic) breast cancer or bilateral breast cancer. * Inflammatory breast cancer. * Has received prior any anti-tumor therapy within the past 12 months prior to signing informed consent, including chemotherapy, targeted therapy, radiation therapy, immunotherapy, biotherapy and TAE. * Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \[CTLA-4\], and/or anti-VEGFR agent. * Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. * Major surgical procedure within 4 weeks prior to initiation of study treatment. * Has a history of autoimmune disease. * Has a history of hypertension that not well controlled by antihypertensive treatment * Has a history of myocardial infarction, severe/unstable angina pectoris, NYHA Class 2 or above cardiac insufficiency, clinically significant supraventricular or ventricular arrhythmia, or symptomatic congestive heart failure within the last 6 months. * Has a history of (non-infectious) pneumonitis, interstitial lung disease or uncontrollable systematicness diseases. * Administration of a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study. * Has a known history of Human Immunodeficiency Virus (HIV). * Has known active Hepatitis B, Hepatitis C or Autoimmune hepatitis. * Severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia. * Has active infection (CTCAE≥2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment. * Has evidence of active tuberculosis within 1 year prior to initiation of study treatment. * Prior allogeneic stem cell or solid organ transplantation. * Peripheral neuropathy grade ≥2. * Has clinically significant intestinal obstruction. * Arterial/venous thrombosis events that occurred within 3 months before enrollment, such as cerebrovascular accidents, deep vein thrombosis, or pulmonary embolism. * Has hemoptysis symptoms within 2 months before enrollment and the maximum daily hemoptysis ≥ 2.5 ml. * Clinically significant bleeding symptoms or clear bleeding tendency occurred within 3 months before enrollment. * Has known genetic or acquired bleeding or thrombotic tendency. * Abnormal coagulation (INR\>1.5 or APTT\>1.5 x ULN) with bleeding tendency, receiving thrombolysis or anticoagulation therapy, or requiring long-term antiplatelet therapy. * Has a known hypersensitivity to the components of the study treatment or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins. * Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial. * History of neurological or psychiatric disorders, including epilepsy or dementia. * Any other situation evaluated by researchers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pCR rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery | Up to approximately 28 weeks | pCR rate (ypT0/Tis ypN0) is defined as the percentage of participants without residual invasive tumor on hematoxylin and eosin evaluation of breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery in all participants. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| pCR rate using the definition of ypT0/Tis (i.e., absence of invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement) at the time of definitive surgery | Up to approximately 28 weeks | pCR rate (ypT0/Tis) is defined as the percentage of participants without invasive cancer in the breast irrespective of ductal carcinoma in situ or nodal involvement following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery in all participants. |
| Objective Response Rate (ORR) | Up to approximately 28 weeks | ORR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR. ORR was assessed by the investigator according to RECIST version 1.1 and is based on BOR, which is defined as best response recorded from start of study treatment until definitive surgery or disease progression. |
| Event-Free Survival (EFS) | Up to approximately 3 years | EFS is defined as the time from start of study treatment to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause. |
| Invasive Disease-Free Survival (iDFS) | Up to approximately 3 years | iDFS events are defined as follows: (1) Ipsilateral invasive breast tumor recurrence. (2) Ipsilateral local-regional invasive breast cancer recurrence. (3) Ipsilateral second primary invasive breast cancer. (4) Contralateral invasive breast cancer. (5) Distant recurrence. (6) Death attributable to any cause. |
| Adverse events (AEs) | Up to approximately 37 weeks | AEs were graded according to the National Cancer Institute's Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0. In general, AEs are graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE. The type, grade and frequency of AEs will be reported. |
Countries
China
Contacts
Primary ContactTing Luo, MD
Outcome results
None listed